Cancer News and Research

Latest Cancer News and Research

SU2C, Virgin America enter partnership to raise awareness and funds for cancer research

Stand Up To Cancer (SU2C) and Virgin America, the California-based airline that is reinventing travel, today announce a unique partnership to raise awareness and funds for cancer research. As SU2C's Official Domestic Airline partner, Virgin America (with Virgin Unite) has pledged to support SU2C's mission through a multi-year in-kind travel partnership, Company fundraising and other joint efforts to drive awareness and funding for lifesaving cancer research.

27 Aug 2010

NICE suggests bortezomib, thalidomide for multiple myeloma patients

The National Institute for Health and Clinical Excellence (NICE) has released draft guidance which recommends the drugs bortezomib and thalidomide as first-line therapies for some patients with multiple myeloma, a type of cancer that affects cells in the bone marrow.

27 Aug 2010

Veterans Affairs partners with NIH to grant award for substance abuse research in military personnel

The Department of Veterans Affairs is partnering with the National Institutes of Health (NIH) to award $6 million in grants for research examining the link between substance abuse and military deployments and combat-related trauma.

26 Aug 2010

China PharmaHub signs distribution agreement for radioactive glass sphere treatment for liver cancer

China PharmaHub Corp. ("PharmaHub"), which has recently merged with World Wide Relics which has changed its name to China PharmaHub Corp, and is in the process of obtaining approval from FINRA to trade under its new name with a new symbol, announced today that it has signed an Exclusive Distribution Agreement ("Agreement") with a world leader in precision glass technology which can be utilized to manufacture high precision radioactive glass spheres that emit alpha, beta or gamma radiation, either individually or in combination, for the treatment of malignant tumors of the liver.

26 Aug 2010

Aethlon Medical receives approval for Chronic HCV Infection treatment

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that the Medanta Independent Ethics Committee (MIEC) at Medanta, The Medicity Institute (Medicity) has approved a treatment program entitled "Use of the Aethlon Hemopurifier in Treating Chronic HCV Infection in Combination with Standard of Care (SOC) Drug Therapy."

26 Aug 2010

Seven year Aspirin for cancer trial

A large clinical trial looking at the cancer preventive actions of aspirin is underway. The seven year study will include six regional centers from Victoria including Ballarat, Bendigo, Geelong, Warrnambool, Traralgon and Shepparton. The ASPirin for Reducing Events in the Elderly (ASPREE) study will involve about 19,000 participants from Australia and the United States.

26 Aug 2010

Bio-Reference Laboratories third-quarter revenues increase 25% to $121,719

Bio-Reference Laboratories, Inc. (Except for Per Share Data or where otherwise noted, numbers are in thousands) announced that the Company recorded current quarter revenues of $121,719, the best ever quarter in terms of revenues in corporate history and an increase of 25% over the $97,424 recorded in the third quarter, fiscal year 2009.

26 Aug 2010

Preferred Imaging installs Naviscan Positron Emission Mammography scanner in new Plano facility

Preferred Imaging Centers has installed the Naviscan PEM scanner into its newest facility in Plano, TX, adding a dedicated breast imaging modality to its array of diagnostic tools. PEM (Positron Emission Mammography) scanners are high-resolution breast PET systems that show the location as well as the metabolic phase of a lesion. The metabolic view assists physicians in making the optimal patient care decision by providing an unprecedented ability to distinguish between benign and malignant lesions, what researchers term “specificity.”

26 Aug 2010

First World Congress on Ergothioneine to be held in Los Angeles, California in July 2011

OXIS INTERNATIONAL, INC. is proud to announce that it has initiated active planning for the First World Congress on Ergothioneine, to be held in Los Angeles, California in July 2011 (the specific date will be announced at a later date).

26 Aug 2010

NeoPharm second-quarter net loss decreases to $0.8 million

NeoPharm, Inc., a publicly traded biopharmaceutical company dedicated to the research, development and commercialization of new and innovative therapeutic applications of drugs for various forms of cancer and other diseases, today announced its second quarter 2010 financial results.

26 Aug 2010

Affordable Care Act that mandates free preventative services goes into effect in September

Starting in September, President Obama's Affordable Care Act will go into effect. The act mandates free preventative services such as cholesterol or breast cancer screenings and tetanus shots. But the question is, will doctors and patients take advantage of these new preventative services? "Unfortunately, thanks to our American healthcare system, we have been programmed to focus on treatment and not prevention," said Dr. David Samadi, a urologic oncologist specializing in prostate cancer treatment and robotic surgery, who is also the Chief of Robotics and Minimally Invasive Surgery at The Mount Sinai Medical Center in New York City.

26 Aug 2010

EDAP TMS introduces Albatherm HIFU device for prostate cancer in Chinese healthcare market

EDAP TMS SA, the global leader in therapeutic ultrasound, announced today that it will expand into the rapidly growing Chinese healthcare market with its Albatherm HIFU device for the treatment of prostate cancer. Ablatherm HIFU will be distributed throughout China by Shaw Han Biomedical Co. Ltd.

26 Aug 2010

FDA approves Chelsea Therapeutics' Phase II protocol for CH-4051 antifolate in rheumatoid arthritis

Chelsea Therapeutics International, Ltd. announced confirmation by the U.S. Food and Drug Administration (FDA) that its proposed Phase II protocol for CH-4051 in rheumatoid arthritis has been approved by the agency.

26 Aug 2010

FDA notification confirms acyclovir Lauriad for oro-facial herpes labialis

BioAlliance Pharma SA, a company dedicated to the supportive care and treatment of cancer patients, today announces that the US Food and Drug Administration (FDA) considers the positive results of the pivotal phase III study with acyclovir Lauriad acceptable to submit a 505(b)(2) New Drug Application of the product in the United States.

26 Aug 2010

CreAgri receives patent for Hydroxytyrosol for skin damage by UV exposure

CreAgri, Inc. announced today that the company has received a Patent by the Australian Patent Office, Patent Number 2003249719, which covers the protective effects provided by Hydroxytyrosol against skin damage caused by UV exposure.

26 Aug 2010

Psychiatric Foundation program recognizes PSE as innovator for addressing cognitive, behavioral disabilities

The Partnership for Workplace Mental Health this month recognized Puget Sound Energy as an innovator for the utility's disability case management approach to address the effects of psychiatric and cognitive functioning issues on employee behavior and work performance.

26 Aug 2010

Saint Thomas Health Services to offer program for neurosurgical patients’ better care

August is Neurosurgery Outreach Month, an effort to increase the public's knowledge about the powerful effects of neurosurgery, many of which are taking place at Saint Thomas Health Services in Tennessee.

26 Aug 2010

Data from PLX4032 Phase 1 clinical trial in melanoma patients with BRAF mutation published

Plexxikon today announced publication of data from the Phase 1 clinical trial of PLX4032 (RG7204), confirming that treatment of metastatic melanoma patients with the BRAF V600E mutation resulted in significant tumor shrinkage in the majority of patients. Specifically, in the melanoma extension cohort of the study, nearly all patients showed some response; 81 percent of patients had tumor shrinkage of at least 30 percent.

26 Aug 2010

Treating metastatic melanoma tumors with specific genetic signature shows promising results

Use of an experimental targeted drug to treat metastatic melanoma tumors with a specific genetic signature was successful in more than 80 percent of patients in a phase 1 clinical trial.

26 Aug 2010

PLX4032 therapy results in tumor shrinkage in metastatic melanoma patients

A multicenter study has concluded that treatment with a new targeted therapy called PLX4032 (also called RG7204) resulted in significant tumor shrinkage in 80 percent of patients with advanced melanoma.

26 Aug 2010

Cancer News and Research

Latest Cancer News and Research

SU2C, Virgin America enter partnership to raise awareness and funds for cancer research

NICE suggests bortezomib, thalidomide for multiple myeloma patients

Veterans Affairs partners with NIH to grant award for substance abuse research in military personnel

China PharmaHub signs distribution agreement for radioactive glass sphere treatment for liver cancer

Aethlon Medical receives approval for Chronic HCV Infection treatment

Seven year Aspirin for cancer trial

Bio-Reference Laboratories third-quarter revenues increase 25% to $121,719

Preferred Imaging installs Naviscan Positron Emission Mammography scanner in new Plano facility

First World Congress on Ergothioneine to be held in Los Angeles, California in July 2011

NeoPharm second-quarter net loss decreases to $0.8 million

Affordable Care Act that mandates free preventative services goes into effect in September

EDAP TMS introduces Albatherm HIFU device for prostate cancer in Chinese healthcare market

FDA approves Chelsea Therapeutics' Phase II protocol for CH-4051 antifolate in rheumatoid arthritis

FDA notification confirms acyclovir Lauriad for oro-facial herpes labialis

CreAgri receives patent for Hydroxytyrosol for skin damage by UV exposure

Psychiatric Foundation program recognizes PSE as innovator for addressing cognitive, behavioral disabilities

Saint Thomas Health Services to offer program for neurosurgical patients’ better care

Data from PLX4032 Phase 1 clinical trial in melanoma patients with BRAF mutation published

Treating metastatic melanoma tumors with specific genetic signature shows promising results

PLX4032 therapy results in tumor shrinkage in metastatic melanoma patients

Industry Focus: Cell & Gene Therapy eBook

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Todd Bauman and Chris Povich

Cancer News and Research

Latest Cancer News and Research

Industry Focus: Cell & Gene Therapy eBook

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Todd Bauman and Chris Povich

Newsletters you may be interested in